Buprenorphine

633 interactions 533 explained in plain English 652 cited references

Also sold as: Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Ensitrelvir Posaconazole Piperaquine Pimozide Phenelzine

22 Contraindicated 601 Major 10 Moderate

All (633) Contraindicated (22) Major (601) Moderate (10)

Contraindicated

Buprenorphine Bepridil Explained An increased risk of QT interval prolongation Details Buprenorphine Cisapride Propulsid® Explained Increased risk of QT interval prolongation Details Buprenorphine Dronedarone Multaq Explained Increased risk of QT interval prolongation Details Buprenorphine Ensitrelvir Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Buprenorphine Fluconazole Diflucan Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Isocarboxazid Marplan Explained An increased risk of CNS depression Details Buprenorphine Ketoconazole Extina Explained Increased buprenorphine exposure, an increased risk of buprenorphine-related adverse events and an increased risk of QT interval p... Details Buprenorphine Levoketoconazole Recorlev Explained An increased risk of QT interval prolongation and torsades pointes, an increased CYP3A4 substrate exposure and an increased risk o... Details Buprenorphine Mesoridazine Explained Increased risk of CNS depression and an increased risk of QT interval prolongation Details Buprenorphine Naltrexone ReVia Explained Precipitation of opioid withdrawal symptoms; decreased opioid effectiveness Details Buprenorphine Phenelzine Nardil Explained An increased risk of serotonin syndrome Details Buprenorphine Pimozide Explained Increased risk of CNS depression and an increased risk of QT interval prolongation Details Buprenorphine Piperaquine Explained An increased risk of QT interval prolongation Details Buprenorphine Posaconazole Noxafil Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Safinamide Xadago Explained Increased risk of serotonin syndrome Details Buprenorphine Samidorphan Explained Decreased opioid efficacy and precipitation of opioid withdrawal Details Buprenorphine Saquinavir Explained An increased risk of QT interval prolongation Details Buprenorphine Sparfloxacin Explained An increased risk of QT interval prolongation Details Buprenorphine Terfenadine Explained An increased risk of QT interval prolongation Details Buprenorphine Tranylcypromine Parnate Explained An increased risk of serotonin syndrome or opioid-related toxicity and an increased risk of CNS depression Details Buprenorphine Ziprasidone Geodon Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of respiratory and CN... Details Buprenorphine Ketoconazole Topical Extina® Foam Increased buprenorphine exposure, an increased risk of buprenorphine-related adverse events and an increased risk of QT interval p... Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.